ASH 2019 | Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results

David Steensma

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a clinical trial of H3B-8800, a splicing modulator, in myeloid cancers (NCT02841540). This phase I, open-label, first-in-human study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of H3B-8800 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter